B群脑膜炎球菌疫苗(Novartis Pharma AG)(Meningococcal group B vaccine(GlaxoSmithKline Biologicals SA)) - 在研适应症：脑膜炎，脑膜炎球菌感染_专利_临床

概要

基本信息

药物类型

灭活疫苗、预防性疫苗

别名

MenB、MenB+OMV NZ、Meningococcal B recombinant vaccine

+ [8]

靶点-

作用机制

免疫刺激剂

治疗领域

感染神经系统疾病

在研适应症

脑膜炎脑膜炎球菌感染

非在研适应症

传染性红斑遗传性补体缺乏病内脏异位综合征+ [1]

原研机构

Novartis AG

在研机构

GSK PlcGlaxosmithkline Vaccines SrlGlaxoSmithKline Biologicals SA

+ [1]

非在研机构

Novartis AGNovartis Vaccines & Diagnostics, Inc.

最高研发阶段批准上市

首次获批日期

欧盟 (2013-01-13),

脑膜炎球菌感染

最高研发阶段(中国)临床申请

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 6741

Sequence Code 23917

Sequence Code 58469

关联

67

项与 B群脑膜炎球菌疫苗(Novartis Pharma AG) 相关的临床试验

NCT06647407 / Recruiting临床1/2期

A Parallel-group Prevention, Phase II, Partially Blinded, Multi-stage Study to Investigate the Immunogenicity and Safety of Pentavalent Meningococcal ABCYW Vaccine Formulations Compared With Licensed Meningococcal Vaccines When Administered Alone in Healthy Children (2 to 9 Years of Age) or Concomitantly With Routine Pediatric Vaccines in Toddlers (12 to 15 Months of Age) and Infants (2 Months of Age).

This study is the first study of Sanofi's Pentavalent Meningococcal ABCYW vaccine clinical development program to be conducted in the pediatric population below 10 years of age. The aim of the study is to assess 2 formulations of the MenPenta vaccine compared to licensed meningococcal vaccines when administered alone in children (Stage 1) or concomitantly with routine pediatric vaccines in toddlers (Stage 2) and infants (Stage 3).
Study details include:
The study duration per participant will be up to 12 months for children in Stage 1 and toddlers in Stage 2 and 16 to-19 months for infants in Stage 3.

开始日期2024-11-05

申办/合作机构

Sanofi Pasteur

NCT06446752 / Not yet recruiting临床3期IIT

A Phase 3 Randomized, Observer-Blind, Placebo-Controlled Study to Assess Efficacy of Meningococcal Group B (rMenB+OMV NZ (Bexsero)) in Preventing Gonococcal Infection Among South African Cis-Gender Women

This proposed 2-arm randomized evaluation of two doses of 4CMenB vaccine versus placebo at Enrollment and Month 2 is designed as a proof-of-concept study to inform potential use for dual meningococcal B and gonococcal prevention, and to inform Neisseria gonorrheae vaccine development.

开始日期2024-08-01

申办/合作机构

University of Washington

[+2]

NCT06025487 / Recruiting临床2期IIT

Immunogenicity and Safety of a Meningococcal Serogroup B Vaccine in Adult Patients with Asplenia

Patients without a spleen (asplenia) experience an increased risk for septicaemia from encapsulated bacteria, which is associated with a high mortality rate. Meningococcal bacteria can cause such infections and serogroup B is the dominant meningococcal subtype in Europe. Therefore, vaccination for risk populations like patients without a spleen is a pressing matter. Considering the effectiveness of the meningococcal serogroup B vaccine, data for this high-at-risk population is currently lacking. The aim of this study is to evaluate the meningococcal B vaccine (BEXSERO®) in patients without a spleen compared to a healthy control group. A total of 40 patients and 40 healthy persons will receive a two-dose schedule of BEXSERO® with a one-month interval between doses. The effectiveness of the vaccine will be determined by measuring antibodies against different meningococcal strains in the blood of the patient. The amount of antibodies one month after second vaccination will be compared between patients and healthy persons. The most reliable assay to determine antibodies against meningococcal strains is the human serum bactericidal assay which will be carried out in a reference laboratory. Other end points are the persistence of antibodies after six months and the cellular immune response. The cellular immune response will be assessed by measuring the proliferation of certain immune cells like lymphocytes and the amount of produced cytokines (signalling proteins) after vaccination. In addition, the safety of the vaccine will be evaluated by documenting all adverse reactions to the vaccine. Overall, this study will be the first to assess the effectiveness of the meningococcal B vaccine in this high-at-risk population and provide data for vaccination guidelines.

开始日期2024-03-12

申办/合作机构

Medical University of Vienna

100 项与 B群脑膜炎球菌疫苗(Novartis Pharma AG) 相关的临床结果

登录后查看更多信息

100 项与 B群脑膜炎球菌疫苗(Novartis Pharma AG) 相关的转化医学

登录后查看更多信息

100 项与 B群脑膜炎球菌疫苗(Novartis Pharma AG) 相关的专利（医药）

登录后查看更多信息

530

项与 B群脑膜炎球菌疫苗(Novartis Pharma AG) 相关的文献（医药）

2024-12-31·Human Vaccines & Immunotherapeutics

Policies for the immunization against serogroup B meningococcus for adolescents immunized during the first two years of life: A mini review

Review

作者: Stefanizzi, Pasquale ; Palmieri, Claudia ; Moscara, Lorenza ; Tafuri, Silvio

Two vaccines are available to prevent serogroup B meningococcal disease, i.e. the four-component meningococcal serogroup B vaccine (4CMenB) and the bivalent-factor-H-binding-protein meningococcal serogroup B vaccine (MenB-fHbp). Currently, 4CMenB is offered as part of routine infant immunization schedules. Available immunogenicity data showed a progressive decline in protective serum bactericidal antibodies (SBA) titers, with a re-enhancement following a booster dose during infancy. Responses did not seem to be long-lasting and vaccinated individuals might be at risk of meningococcal diseases duriṇg adolescence. Only one study evaluated the possibility to administer a single booster dose to immunocompetent adolescents who received a primary series during infancy. Despite a high proportion of enrollees achieving protective SBA levels 28 days post-booster, titers tended to decrease 1 year after. Immunocompetent adolescents who received a primary series and a booster during the first two years of life might rather benefit from re-vaccination against MenB; current evidence does not support the possibility of a booster.

2024-12-31·Human vaccines & immunotherapeutics

Available evidence on the co-administration of the four-component meningococcal B vaccine (4CMenB) with three vaccines at the same visit among pediatric individuals

Review

作者: Prato, Rosa ; Russo, Rocco ; Bonanni, Paolo ; Gabutti, Giovanni ; Marchetti, Federico ; Vitale, Francesco ; Castagna, Stefano ; Giuffrida, Sandro

Vaccine co-administration is a useful strategy for improving vaccine coverage and adherence. In Italy, an update to the national immunization program (NIP) in 2023 included recommendations for co-administration of pediatric vaccines, including the four-component vaccine for meningococcus B (4CMenB), pneumococcal conjugate vaccine (PCV), hexavalent vaccines, and oral rotavirus vaccines. Safety is a major concern when considering vaccine co-administration; therefore, a literature review of the available evidence on 4CMenB co-administration with PCV, hexavalent/pentavalent, and rotavirus vaccines was performed. Of 763 publications screened, two studies were reviewed that reported safety data on 4CMenB co-administration with PCV, hexavalent/pentavalent, and rotavirus vaccines in infants aged 0-24 months. Overall, these studies supported that there were no significant safety signals when co-administering 4CMenB with PCV, hexavalent/pentavalent, and rotavirus vaccines, compared with individual vaccination. This review provides key insights for healthcare professionals on the tolerability of co-administering 4CMenB with routine vaccines.

2024-12-31·Human Vaccines & Immunotherapeutics

4CMenB journey to the 10-year anniversary and beyond

Review

作者: Toneatto, Daniela ; Rappuoli, Rino ; Bambini, Stefania ; Taha, Muhamed-Kheir ; Nolan, Terry ; Pizza, Mariagrazia ; Martinón-Torres, Federico ; Muzzi, Alessandro ; Borrow, Ray ; Abitbol, Véronique ; Serino, Laura

The 4-component meningococcal serogroup B (MenB) vaccine, 4CMenB, the first broadly protective, protein-based MenB vaccine to be licensed, is now registered in more than 50 countries worldwide. Real-world evidence (RWE) from the last decade confirms its effectiveness and impact, with infant immunization programs showing vaccine effectiveness of 71-95% against invasive MenB disease and cross-protection against non-B serogroups, including a 69% decrease in serogroup W cases in 4CMenB-eligible cohorts in England. RWE from different countries also demonstrates the potential for additional moderate protection against gonorrhea in adolescents. The real-world safety profile of 4CMenB is consistent with prelicensure reports. Use of the endogenous complement human serum bactericidal antibody (enc-hSBA) assay against 110 MenB strains may enable assessment of the immunological effectiveness of multicomponent MenB vaccines in clinical trial settings. Equitable access to 4CMenB vaccination is required to better protect all age groups, including older adults, and vulnerable groups through comprehensive immunization policies.

57

项与 B群脑膜炎球菌疫苗(Novartis Pharma AG) 相关的新闻（医药）

2024-11-29

·PMLiVE

GSK granted EC approval for meningococcal disease vaccine Menveo

GSK’s fully liquid presentation of its meningococcal vaccine Menveo has been approved by the European Commission (EC) to protect individuals aged two years and older against invasive meningococcal disease (IMD). The single-vial presentation is designed to simplify the vaccination process by offering healthcare providers an option that does not require reconstitution before use. IMD is an uncommon but serious illness caused by the bacterium Neisseria meningitidis. It is a major cause of meningitis and septicaemia, and can result in long-term consequences such as neurological damage, amputations, hearing loss and nervous system problems. Although anyone can contract IMD, babies, young children and those who are in their late teens and early adulthood are among those at the highest risk. Menveo is designed to help protect IMD caused by bacterial groups A, C, W, and Y and has already been approved in the EU as a powder and solution that are mixed together to make a solution for injection. The EU regulator’s decision on the new presentation follows a recent recommendation from the European Medicines Agency’s human medicines committee and was supported by positive results from two phase 2b trials, which showed that the fully liquid form of the vaccine had comparable immunogenicity, tolerability and a comparable safety profile to the existing formulation. The original presentation of Menveo, which is also approved for use in individuals aged from two years, is unaffected by the approval. Philip Dormitzer, head of global vaccines research and development at GSK said the company is “dedicated to finding innovative solutions that simplify immunisation and support vaccine uptake”. “We remain committed to safeguarding individuals from bacterial meningitis, and we will persist in our efforts to prevent this devastating disease among at-risk populations in the EU,” he said. GSK also has an investigational five-in-one meningococcal vaccine in its pipeline which combines the antigenic components of Menveo and its approved meningococcal group B vaccine Bexsero. The candidate, MenABCWY, was accepted for regulatory review by the US Food and Drug Administration in April, following positive results from a phase 3 trial involving individuals aged ten to 25 years.

临床结果上市批准临床2期疫苗临床3期

2024-11-29

·Pharmaceutical Technology

UK reports near eradication of meningitis C amid declining vaccine uptake

Vaccines are available as part of the UK routine immunisation schedule to prevent some types of meningitis. Credit: Billion Photos via Shutterstock. New data from the UK Health Security Agency (UKHSA) indicates significant progress in combating meningitis caused by meningococcal group C (MenC), with cases falling by 99% since the introduction of a routine vaccination programme in 1999. Between July 2023 and June 2024, only three MenC cases were recorded. Other meningococcal strains, including groups A, W, and Y, also remain at low levels due to widespread immunisation. However, meningococcal group B (MenB)—responsible for the majority of meningitis and septicaemia cases in the UK—continues to be a public health concern. Meningitis is the inflammation of the tissues surrounding the brain and spinal cord. It can be fatal and requires immediate medical care. Of the 341 confirmed cases of meningococcal disease reported in England over the last year, 88% (301 cases) were caused by MenB. Despite the availability of a vaccine, uptake has been declining. In 2022-2023, 91% of children received the first two doses of the MenB vaccine, down by 0.5% from the previous year while booster coverage fell to 87.6%. Adolescent vaccination rates also show room for improvement. The MenACWY vaccine, which targets groups A, C, W, and Y, saw uptake rates of 68.6% in year nine and 73.4% in year ten. Dr Shamez Ladhani, a consultant epidemiologist at UKHSA, cautioned that while progress against MenC is promising, continued vigilance is needed. “Thanks to the power of vaccines, we are now on the brink of defeating meningococcal C disease in the UK, but the fight against these deadly diseases that cause meningitis and septicaemia continues with meningococcal B still causing most of the 341 cases last year,” Ladhani said. The UK’s meningitis vaccination schedule includes the Hib/MenC vaccine, administered to children at one year of age, and the MenB vaccine, given at eight weeks, 16 weeks, and one year. Teenagers receive the MenACWY vaccine in school years nine and ten. The MenB vaccine, marketed as Bexsero, is produced by GSK while the MenC vaccine component is part of a combination vaccine developed by Pfizer . Both vaccines have contributed significantly to reducing meningococcal disease cases in the UK. The success in reducing MenC cases demonstrates the effectiveness of vaccination programmes, but the challenges with MenB mirror issues seen globally. Epidemics of meningitis are seen across the world, particularly in sub-Saharan Africa, and vaccine hesitancy and logistical barriers remain significant obstacles to achieving higher coverage rates.

疫苗上市批准

2024-10-31

·GBIHealth

葛兰素史克Y24Q3财报速读：疫苗业务下滑15%，肿瘤板块增长94%

2024年10月30日，葛兰素史克（NYSE：GSK）发布了2024年第三季度（报告期）财务业绩。期内公司收入80亿英镑（约合104.96亿美元），同比增长2%（按固定汇率计算，下同）。前三季度，疫苗下滑15%，肿瘤增长94% 疫苗销售额下降了 15%，而专科药品（包括肿瘤、HIV、呼吸/免疫板块）和普药的销售收入分别增长19%和7%。报告期内，公司疫苗业务收入26.5亿英镑。其中带状疱疹疫苗Shingrix（重组带状疱疹疫苗）销售额7.39亿英镑，同比下降7%； RSV疫苗Arexvy销售额1.88亿英镑，同比下降72%，主要由于免疫实践咨询委员会（ACIP）指南变化、美国 COVID 疫苗接种的优先顺序的调整以及Arexvy因2023年第三季度上市难以比较的因素。两款脑膜炎疫苗Bexsero、Menveo销售额分别为3.34亿英镑（+30%）和1.73亿英镑（+7%）。专科药品业务Q3收入29.66 亿英镑，同比增长19%。其中艾滋病板块收入17.5亿英镑，同比增长12%；肿瘤板块收入3.73亿英镑，同比增长94%；呼吸/免疫及其他板块收入8.43亿英镑，同比增长14%。肿瘤板块的强劲增长主要由以下产品驱动：强效选择性JAK抑制剂Ojjaara（momelotinib）销售额9800万英镑，用于治疗骨髓纤维化贫血； PD-1单抗Jemperli（Dostarlimab）销售额1.3亿英镑，主要由于获批子宫内膜癌适应证驱动； PARP抑制剂则乐（尼拉帕利）销售额1.44英镑，主要由于美国的高定价和美国市场以外的强劲需求驱动。艾滋病板块主要由LAI长效注射剂投资组合（Cabenuva、Apretude）和Dovato的强劲销售推动：长效注射剂Cabenuva（2.45亿英镑，+40%）、Apretude（6900万英镑，+95%）实现销售额3.14亿英镑，占本季度总增长的50%； Dovato销售额5.67亿英镑。预计明年，公司有5个核心的新产品/适应证将获得批准： Blenrep（BCMA ADC）、Depemokimab（IL-5单抗）、美泊利珠单抗（IL-5单抗）、Gepotidacin（全新机制抗生素）和预防脑膜炎的五合一疫苗（MenABCWY）。 4款药品Ⅱ期临床终止： 24价肺炎球菌疫苗GSK5101956、淋病疗法GSK4348413、单纯疱疹病毒疫苗GSK3943104和镇痛CCL17抗体GSK3858279。全球医疗情报领导者解锁隐藏在数据中的商业潜力关于 G B I ” 自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。联系我们投稿 | 发稿 | 媒体合作 ▶ zhangxinyue13@baidu.com 数据库 | 咨询服务 | 资讯追踪 ▶ 点击左下“阅读原文”完成表单填写点击阅读原文，解锁完整双语新闻

疫苗财报

100 项与 B群脑膜炎球菌疫苗(Novartis Pharma AG) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07AH09	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
脑膜炎	加拿大	GSK Plc	2014-02-26
脑膜炎球菌感染	欧盟	GSK Plc	2013-01-13
脑膜炎球菌感染	冰岛	GSK Plc	2013-01-13
脑膜炎球菌感染	列支敦士登	GSK Plc	2013-01-13
脑膜炎球菌感染	挪威	GSK Plc	2013-01-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
遗传性补体缺乏病	临床3期	意大利	Novartis AG	2014-05-01
遗传性补体缺乏病	临床3期	波兰	Novartis AG	2014-05-01
遗传性补体缺乏病	临床3期	俄罗斯	Novartis AG	2014-05-01
遗传性补体缺乏病	临床3期	西班牙	Novartis AG	2014-05-01
遗传性补体缺乏病	临床3期	英国	Novartis AG	2014-05-01
内脏异位综合征	临床3期	意大利	Novartis AG	2014-05-01
内脏异位综合征	临床3期	波兰	Novartis AG	2014-05-01
内脏异位综合征	临床3期	俄罗斯	Novartis AG	2014-05-01
内脏异位综合征	临床3期	西班牙	Novartis AG	2014-05-01
内脏异位综合征	临床3期	英国	Novartis AG	2014-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04722003 (CTgov)	临床2期	淋病	52	Meningococcal Group B Vaccine (4CMenB)	鏇廠衊構夢繭艱積醖衊(糧艱遞鏇衊糧遞鬱繭壓) = 選壓顧築衊製糧糧膚膚築願製鬱鏇壓艱窪鏇壓 (構夢衊積鬱艱顧鏇衊壓, 艱淵選鏇築夢夢願遞網 ~ 衊範鏇襯糧鹹構製膚選) 更多	-	2024-11-05
				Placebo (Placebo)	鏇廠衊構夢繭艱積醖衊(糧艱遞鏇衊糧遞鬱繭壓) = 衊憲鬱夢製鬱餘製鏇膚築願製鬱鏇壓艱窪鏇壓 (構夢衊積鬱艱顧鏇衊壓, 夢願遞襯齋鑰築鬱廠襯 ~ 遞夢艱鏇遞憲窪鬱鬱觸) 更多
NCT04502693 (CTgov)	临床3期	脑膜炎球菌感染	3,657	rMenB+OMV NZ vaccine+Y Conjugate Vaccine (MenACWY) (MenB_0_2_6 Group)	鹽構齋觸壓簾範積顧顧(艱鏇壓憲糧齋網顧鹹夢) = 選鹽衊窪簾膚衊壓夢鬱繭壓製築膚壓衊艱蓋鏇 (製鏇衊遞壓廠簾蓋願醖, 齋蓋築構製製醖鹹鹹願 ~ 餘窪網繭獵積繭齋窪鑰) 更多	-	2024-03-05
				Placebo+rMenB+OMV NZ vaccine+Y Conjugate Vaccine (MenACWY) (MenB_0_6 Group)	鹽構齋觸壓簾範積顧顧(艱鏇壓憲糧齋網顧鹹夢) = 窪廠窪觸積網積選選選繭壓製築膚壓衊艱蓋鏇 (製鏇衊遞壓廠簾蓋願醖, 積鬱醖衊膚選積窪觸廠 ~ 襯選繭餘襯襯壓築襯衊) 更多
NCT03493919 (CTgov)	临床4期	流行性脑脊髓膜炎	1,021	rMenB+OMV NZ vaccine (rMenB+OMV NZ Group)	艱鹽蓋積網鹹簾築積構(構憲衊衊鹹淵觸遞齋顧) = 顧齋製鏇餘窪鑰壓鹹衊壓糧網艱鏇壓網選積鑰 (遞顧窪築憲遞簾網鑰積, 觸淵選鬱襯構築構鏇選 ~ 鹹艱獵憲選壓襯鑰襯鏇) 更多	-	2023-07-17
				Y Conjugate Vaccine (MenACWY) (MenACWY 1 Group)	艱鹽蓋積網鹹簾築積構(構憲衊衊鹹淵觸遞齋顧) = 鏇簾網網鏇網憲築鹽製壓糧網艱鏇壓網選積鑰 (遞顧窪築憲遞簾網鑰積, 鏇繭獵衊醖網膚壓憲鑰 ~ 範網壓廠顧繭蓋鹽窪鏇) 更多
NCT04084769 (CTgov)	临床3期	接种疫苗	570	Meningococcal polysaccharide (serogroups A, C, Y, (Group 1: MenACYW Conjugate Vaccine)	顧衊糧觸鏇壓襯遞顧窪(夢艱夢鬱窪夢製廠鏇製) = 壓鹽餘淵餘鏇窪遞壓鏇壓鑰繭艱夢艱鏇窪築糧 (夢淵繭簾鏇願蓋遞糧繭, 糧壓鬱簾廠膚觸壓艱簾 ~ 簾遞獵蓋廠繭鹽艱選襯) 更多	-	2021-08-30
				Meningococcal polysaccharide (serogroups A, C, Y, (Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed))	觸淵鏇網餘襯鹹襯繭遞(鹹簾製範鏇窪築顧醖衊) = 艱築廠網壓鹽壓遞鏇觸壓鬱製鏇鏇鏇窪廠選憲 (窪構願遞選構製窪積鬱, 積觸艱獵範觸糧廠廠鬱 ~ 鬱觸鏇鑰醖築蓋願選築) 更多
NCT04094883 (4CMenB, CTgov)	临床4期	淋病	11	Meningococcal Group B Vaccine	鬱衊願願積醖醖繭憲醖(範簾醖鹹夢齋齋鹽簾獵) = 膚襯壓願鬱窪憲製衊窪積壓壓鏇遞觸觸餘遞積 (夢簾淵襯廠繭糧鏇膚鏇, 鬱顧網積築淵襯鹹醖觸 ~ 鹽構窪簾鹽夢糧憲選積) 更多	-	2021-07-15
NCT03089086 (Pubmed \| Clin Infect Dis)	临床4期	脑膜炎球菌感染	34,489	meningococcal B vaccine (Control group (not vaccinated))	範鬱鬱願選艱齋襯窪襯(膚夢鏇膚網廠積觸選製) = 夢鑰窪餘製鏇範遞積壓觸壓廠齋遞構鹽壓構膚 (窪衊壓簾選顧夢範鏇蓋 )	积极	2021-02-15
NCT03089086 (Pubmed \| Br Dent J \| N Engl J Med) 人工标引	临床4期	脑膜炎球菌感染	34,489	4CMenB	齋鬱膚觸網構鹽齋鹽襯(築衊膚餘簾窪醖範築築) = 齋製網製顧製製鬱觸鏇艱顧夢構憲衊願壓衊簾 (糧製廠築窪糧艱襯衊製 )	不佳	2020-01-23
				No Intervention	齋鬱膚觸網構鹽齋鹽襯(築衊膚餘簾窪醖範築築) = 膚築鹽夢築積製膚糧衊艱顧夢構憲衊願壓衊簾 (糧製廠築窪糧艱襯衊製 )
NCT02946385 (CTgov)	临床2期	脑膜炎球菌感染	604	MenABCWY (ABCWY_0_2)	壓齋製築蓋願顧衊積蓋(構獵餘構鏇顧鏇襯艱構) = 糧襯齋壓蓋範製醖窪遞鏇顧範蓋憲鬱膚衊繭構 (觸獵製繭鹹蓋繭壓醖廠, 窪構醖膚襯顧醖壓選艱 ~ 蓋顧夢構獵窪壓鹽選淵) 更多	-	2019-08-20
				MenABCWY (ABCWY_0_2_6)	壓齋製築蓋願顧衊積蓋(構獵餘構鏇顧鏇襯艱構) = 夢積膚鹽願積衊鬱選鑰鏇顧範蓋憲鬱膚衊繭構 (觸獵製繭鹹蓋繭壓醖廠, 遞觸鬱窪齋醖艱糧鏇觸 ~ 醖構艱獵積齋齋廠願窪) 更多
NCT02583412 (Pubmed)	临床4期	-	120	MenB vaccine (Bexsero)	獵範艱鹹築艱願窪廠範(網蓋鬱夢製襯觸襯製齋) = 壓觸鹹齋醖鹽襯廠顧簾範蓋鏇鹽製顧鏇壓壓艱 (糧艱製範構鑰壓鹽鹽繭 )	-	2019-07-03
NCT02106390 (CTgov)	临床3期	脑膜炎球菌感染	750	rMenB+ACWY (rMenB+ACWY Group)	鬱淵築窪鑰蓋壓壓壓鹹(鹽觸窪艱製鏇範範齋構) = 觸鬱廠選衊觸網鬱醖築築範窪衊簾顧選構積憲 (壓鹽壓網壓鏇遞淵鬱蓋, 繭遞鬱憲獵廠鹹選淵蓋 ~ 艱繭選醖構艱淵鬱艱網) 更多	-	2018-08-22
				rMenB+OMV (rMenB Group)	鬱淵築窪鑰蓋壓壓壓鹹(鹽觸窪艱製鏇範範齋構) = 夢餘膚艱鏇範選壓夢醖築範窪衊簾顧選構積憲 (壓鹽壓網壓鏇遞淵鬱蓋, 齋淵繭齋鑰夢築憲夢獵 ~ 餘齋廠夢醖製鑰餘遞淵) 更多